- hos patienter, der ikke er velkontrollerede på inhalationssteroid og korttidsvirkende ß2- agonist
Viani is indicated in the regular treatment of asthma where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: